Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression clinical trial (NCT07412262). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of Chidamide and Ivonescimab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression clinical trial (NCT07412262). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression clinical trial (NCT07412262). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression clinical trial (NCT07412262). Contact the study team or your healthcare provider for specific answers.

Question 5

What are the chances this treatment could help my specific situation?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression clinical trial (NCT07412262). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression clinical trial (NCT07412262). Contact the study team or your healthcare provider for specific answers.

What this study is about